Citations (71)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Dan Zheng, Feixia Gao, Cheng Zhao, Yahong Ding, Yemin Cao, Tianhan Yang, Xuesong Xu & Ze Chen. (2019) Comparative effectiveness of H7N9 vaccines in healthy individuals. Human Vaccines & Immunotherapeutics 15:1, pages 80-90.
Read now
Read now
Angela Domínguez, Pere Godoy & Nuria Torner. (2016) The Effectiveness of Influenza Vaccination in Different Groups. Expert Review of Vaccines 15:6, pages 751-764.
Read now
Read now
Markus Knuf, Geert Leroux-Roels, Hans Rümke, Luis Rivera, Paola Pedotti, Ashwani Kumar Arora, Maria Lattanzi, Dorothee Kieninger & Giovanni Della Cioppa. (2015) Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children . Human Vaccines & Immunotherapeutics 11:2, pages 358-376.
Read now
Read now
Keith S Reisinger, Sandra J Holmes, Paola Pedotti, Ashwani Kumar Arora & Maria Lattanzi. (2014) A dose-ranging study of MF59®-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination. Human Vaccines & Immunotherapeutics 10:8, pages 2395-2407.
Read now
Read now
Karl-Heinz Herbinger, Frank von Sonnenburg, Hans Dieter Nothdurft, Pamela Perona, Astrid Borkowski, Elena Fragapane, Uwe Nicolay & Ralf Clemens. (2014) A phase II study of an investigational tetravalent influenza vaccine formulation combining MF59®. Human Vaccines & Immunotherapeutics 10:1, pages 92-99.
Read now
Read now
Derek T O'Hagan, Tedodore F Tsai & Luis A Brito. (2013) Emulsion based vaccine adjuvants. Human Vaccines & Immunotherapeutics 9:8, pages 1698-1700.
Read now
Read now
Christopher B Fox & Jean Haensler. (2013) An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants. Expert Review of Vaccines 12:7, pages 747-758.
Read now
Read now
Derek T O’Hagan, Gary S Ott, Gary Van Nest, Rino Rappuoli & Giuseppe Del Giudice. (2013) The history of MF59® adjuvant: a phoenix that arose from the ashes. Expert Review of Vaccines 12:1, pages 13-30.
Read now
Read now
Giuseppe Del Giudice, Elena Fragapane, Giovanni Della Cioppa & Rino Rappuoli. (2013)
Aflunov®: a vaccine tailored for pre-pandemic and pandemic approaches against influenza. Expert Opinion on Biological Therapy 13:1, pages 121-135.
Read now
Read now
Angelika Banzhoff & Jeffrey J. Stoddard. (2012) Effective influenza vaccines for children. Human Vaccines & Immunotherapeutics 8:3, pages 398-402.
Read now
Read now
Philip Dormitzer, Theodore Tsai & Giuseppe Del Giudice. (2012) New technologies for influenza vaccines. Human Vaccines & Immunotherapeutics 8:1, pages 45-58.
Read now
Read now
Antonio Crucitti & Theodore F. Tsai. (2011) Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy: A six-month update. Scandinavian Journal of Infectious Diseases 43:11-12, pages 993-993.
Read now
Read now
Joan Puig-Barberà, Silvia Pérez-Vilar & Javier Díez-Domingo. (2011) MF59™-adjuvanted seasonal influenza vaccine in young children. Expert Review of Vaccines 10:11, pages 1519-1528.
Read now
Read now
Articles from other publishers (58)
Eamon O Murchu, Laura Comber, Karen Jordan, Sarah Hawkshaw, Liam Marshall, Michelle O’Neill, Máirín Ryan, Conor Teljeur, Annasara Carnahan, Jaime Jesús Pérez, Anna Hayman Robertson, Kari Johansen, Jorgen de Jonge, Tyra Krause, Nathalie Nicolay, Hanna Nohynek, Ioanna Pavlopoulou, Richard Pebody, Pasi Penttinen, Marta Soler‐Soneira, Ole Wichmann & Patricia Harrington. (2022)
Systematic review of the efficacy, effectiveness and safety of MF59
®
adjuvanted seasonal influenza vaccines for the prevention of laboratory‐confirmed influenza in individuals ≥18 years of age
. Reviews in Medical Virology 33:3.
Crossref
Crossref
Jun-Sang Sunwoo. (2021) Narcolepsy, autoimmunity, and influenza A H1N1 vaccination. encephalitis 1:2, pages 31-35.
Crossref
Crossref
Zhuofan Li, Yiwen Zhao, Yibo Li & Xinyuan Chen. (2021) Adjuvantation of Influenza Vaccines to Induce Cross-Protective Immunity. Vaccines 9:2, pages 75.
Crossref
Crossref
Milena Apetito Akamatsu, Vitor Anselmo Sakihara, Bianca Pereira Carvalho, Aline de Paiva Abrantes, Maria A. Sakauchi Takano, Eduardo Alfredo Adami, Fernando Seiji Yonehara, Patrícia dos Santos Carneiro, Stefanni Rico, Alessandra Schanoski, Maurício Meros, Adrian Simpson, Tony Phan, Christopher B. Fox & Paulo Lee Ho. (2020) Preparedness against pandemic influenza: Production of an oil-in-water emulsion adjuvant in Brazil. PLOS ONE 15:6, pages e0233632.
Crossref
Crossref
Sanjay S. Patel, Svetlana Bizjajeva, Kelly Lindert, Esther Heijnen & Janine Oberye. (2019) Cumulative clinical experience with MF59-adjuvanted trivalent seasonal influenza vaccine in young children. International Journal of Infectious Diseases 85, pages S26-S38.
Crossref
Crossref
Kelly Lindert, Brett Leav, Esther Heijnen, Julia Barrett & Uwe Nicolay. (2019) Cumulative clinical experience with MF59-adjuvanted trivalent seasonal influenza vaccine in young children and adults 65 years of age and older. International Journal of Infectious Diseases 85, pages S10-S17.
Crossref
Crossref
Kathryn Edwards, Germaine Hanquet, Steve Black, Emmanuel Mignot, Christopher Jankosky, Tom Shimabukuro, Elizabeth Miller, Hanna Nohynek & Pieter Neels. (2019) Meeting report narcolepsy and pandemic influenza vaccination: What we know and what we need to know before the next pandemic? A report from the 2nd IABS meeting. Biologicals 60, pages 1-7.
Crossref
Crossref
Tomi O. Sarkanen, Anniina P.E. Alakuijala, Yves A. Dauvilliers & Markku M. Partinen. (2018) Incidence of narcolepsy after H1N1 influenza and vaccinations: Systematic review and meta-analysis. Sleep Medicine Reviews 38, pages 177-186.
Crossref
Crossref
Frank Destefano, Paul A. Offit & Allison Fisher. 2018. Plotkin's Vaccines. Plotkin's Vaccines
1584
1600.e10
.
Matthew Z. Dudley, Daniel A. Salmon, Neal A. Halsey, Walter A. Orenstein, Rupali J. Limaye, Sean T. O'Leary & Saad B. OmerMatthew Z. Dudley, Daniel A. Salmon, Neal A. Halsey, Walter A. Orenstein, Rupali J. Limaye, Sean T. O’Leary & Saad B. Omer. 2018. The Clinician’s Vaccine Safety Resource Guide. The Clinician’s Vaccine Safety Resource Guide
309
314
.
Amanda L. Wilkins, Dmitri Kazmin, Giorgio Napolitani, Elizabeth A. Clutterbuck, Bali Pulendran, Claire-Anne Siegrist & Andrew J. Pollard. (2017) AS03- and MF59-Adjuvanted Influenza Vaccines in Children. Frontiers in Immunology 8.
Crossref
Crossref
Anthony C. Y. Yau, Erik Lönnblom, Jianghong Zhong & Rikard Holmdahl. (2017) Influence of hydrocarbon oil structure on adjuvanticity and autoimmunity. Scientific Reports 7:1.
Crossref
Crossref
Melodie Bonvalet, Hanna M. Ollila, Aditya Ambati & Emmanuel Mignot. (2017) Autoimmunity in narcolepsy. Current Opinion in Pulmonary Medicine 23:6, pages 522-529.
Crossref
Crossref
S. Kommareddy, M. Singh & D.T. O'Hagan. 2017. Immunopotentiators in Modern Vaccines. Immunopotentiators in Modern Vaccines
249
263
.
Ji Hyun Song, Tae Won Kim, Yoo Hyun Um & Seung Chul Hong. (2016) Narcolepsy: Association with H1N1 Infection and Vaccination. Sleep Medicine Research 7:2, pages 43-47.
Crossref
Crossref
David L. Gordon, Dimitar Sajkov, Yoshikazu Honda-Okubo, Samuel H. Wilks, Malet Aban, Ian G. Barr & Nikolai Petrovsky. (2016) Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advax™ delta inulin adjuvant. Vaccine 34:33, pages 3780-3786.
Crossref
Crossref
Birgitte Rahbek Kornum. 2016. Narcolepsy. Narcolepsy
25
33
.
Neal A. Halsey, Kawsar R. Talaat, Adena Greenbaum, Eric Mensah, Matthew Z. Dudley, Tina Proveaux & Daniel A. Salmon. (2015) The safety of influenza vaccines in children: An Institute for Vaccine Safety white paper. Vaccine 33, pages F1-F67.
Crossref
Crossref
Nikolai Petrovsky. (2015) Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs. Drug Safety 38:11, pages 1059-1074.
Crossref
Crossref
Michael G. Agadjanyan, Nikolai Petrovsky & Anahit Ghochikyan. (2015) A fresh perspective from immunologists and vaccine researchers: Active vaccination strategies to prevent and reverse Alzheimer's disease. Alzheimer's & Dementia 11:10, pages 1246-1259.
Crossref
Crossref
María-Teresa Arango, Shaye Kivity, Nancy Agmon-Levin, Gili Givaty, Joab Chapman & Yehuda Shoenfeld. 2015. Vaccines and Autoimmunity. Vaccines and Autoimmunity
291
300
.
Steven Black. (2015) Safety and effectiveness of MF-59 adjuvanted influenza vaccines in children and adults. Vaccine 33, pages B3-B5.
Crossref
Crossref
María-Teresa Arango, Shaye Kivity & Yehuda Shoenfeld. (2015) Is narcolepsy a classical autoimmune disease?. Pharmacological Research 92, pages 6-12.
Crossref
Crossref
Markus Knuf, Geert Leroux-Roels, Hans. C. Rümke, Katia Abarca, Luis Rivera, Maria Lattanzi, Paola Pedotti, Ashwani Arora, Dorothee Kieninger-Baum & Giovanni Della Cioppa. (2015) Safety and immunogenicity of an MF59®-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age. Vaccine 33:1, pages 174-181.
Crossref
Crossref
John J. Treanor. 2015. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases
2000
2024.e6
.
Markus Knuf, Geert Leroux-Roels, Hans. C. Rümke, Katia Abarca, Luis Rivera, Maria Lattanzi, Paola Pedotti, Ashwani Arora, Dorothee Kieninger-Baum & Giovanni Della Cioppa. (2014) Immunogenicity and Tolerability of an MF59-adjuvanted, Egg-derived, A/H1N1 Pandemic Influenza Vaccine in Children 6–35 Months of Age. Pediatric Infectious Disease Journal 33:12, pages e320-e329.
Crossref
Crossref
Terry Nolan, Lulu Bravo, Ana Ceballos, Essack Mitha, Glenda Gray, Beatriz Quiambao, Sanjay S. Patel, Svetlana Bizjajeva, Hans Bock, Nancy Nazaire-Bermal, Eduardo Forleo-Neto, Giovanni Della Cioppa & Vas Narasimhan. (2014) Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59®-adjuvanted influenza vaccine in infants and young children. Vaccine 32:46, pages 6146-6156.
Crossref
Crossref
Sharon E. Frey, Mari Rose Aplasca-De Los Reyes, Humberto Reynales, Nancy Nazaire Bermal, Uwe Nicolay, Vas Narasimhan, Eduardo Forleo-Neto & Ashwani Kumar Arora. (2014) Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine 32:39, pages 5027-5034.
Crossref
Crossref
Luis A. Brito & Derek T. O'Hagan. (2014) Designing and building the next generation of improved vaccine adjuvants. Journal of Controlled Release 190, pages 563-579.
Crossref
Crossref
Michel Lecendreux. (2014) Quality of Life in Children with Narcolepsy and Cataplexy. Sleep Medicine Clinics 9:2, pages 211-217.
Crossref
Crossref
Mike Kidd. (2014) Influenza viruses. Current Opinion in Pulmonary Medicine 20:3, pages 242-246.
Crossref
Crossref
Stephan A. BartMatthew HohenbokenGiovanni Della CioppaVas NarasimhanPhilip R. DormitzerNiranjan Kanesa-thasan. (2014) A Cell Culture–Derived MF59-Adjuvanted Pandemic A/H7N9 Vaccine Is Immunogenic in Adults. Science Translational Medicine 6:234.
Crossref
Crossref
Elke Bergmann-Leitner & Wolfgang Leitner. (2014) Adjuvants in the Driver’s Seat: How Magnitude, Type, Fine Specificity and Longevity of Immune Responses Are Driven by Distinct Classes of Immune Potentiators. Vaccines 2:2, pages 252-296.
Crossref
Crossref
Charlotte I S Barker & Matthew D Snape. (2014) Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action. The Lancet Infectious Diseases 14:3, pages 227-238.
Crossref
Crossref
Steven G Reed, Mark T Orr & Christopher B Fox. (2013) Key roles of adjuvants in modern vaccines. Nature Medicine 19:12, pages 1597-1608.
Crossref
Crossref
Rajesh K. Gupta. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
32
.
Peter Wutzler, Roland Hardt, Markus Knuf & Klaus Wahle. (2013) Targeted Vaccine Selection in Influenza Vaccination. Deutsches Ärzteblatt international.
Crossref
Crossref
D. A. Salmon & N. A. Halsey. (2013) Editorial Commentary: Guillain-Barre Syndrome and Vaccinations. Clinical Infectious Diseases 57:2, pages 205-207.
Crossref
Crossref
Pio Lopez, Yolanda Caicedo, Alexandra Sierra, Sandrine Tilman, Ralf Clemens & Angelika Banzhoff. (2013) Combined Administration of MF59-Adjuvanted A/H5N1 Prepandemic and Seasonal Influenza Vaccines: Long-Term Antibody Persistence and Robust Booster Responses 1 Year after a One-Dose Priming Schedule. Clinical and Vaccine Immunology 20:5, pages 753-758.
Crossref
Crossref
Leonoor Wijnans, Daniel Weibel & Miriam Sturkenboom. (2013) Adjuvanted versus nonadjuvanted influenza vaccines in young children: comparing results from recent clinical trials. Clinical Investigation 3:4, pages 395-408.
Crossref
Crossref
Luis A. Brito, Padma Malyala & Derek T. O’Hagan. (2013) Vaccine adjuvant formulations: A pharmaceutical perspective. Seminars in Immunology 25:2, pages 130-145.
Crossref
Crossref
Christopher B. Fox, Chuong Huynh, Michael K. O’Hara & Adrian Onu. (2013) Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania. Vaccine 31:12, pages 1633-1640.
Crossref
Crossref
Theodore F Tsai. (2013) Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults. Infection & Chemotherapy 45:2, pages 159.
Crossref
Crossref
Anthony E. Fiore, Carolyn B. Bridges, Jacqueline M. Katz & Nancy J. Cox. 2013. Vaccines. Vaccines
257
293
.
S. Grund, O. Wichmann, T. Mertens & H. Hengel. (2012) Konzepte, Wirksamkeit und Perspektiven pandemischer und nichtpandemischer InfluenzaimpfungenConcepts, effectiveness, and perspectives of pandemic and seasonal influenza vaccines. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 56:1, pages 76-86.
Crossref
Crossref
Iván Bihari, Gyula Pánczél, Jozsef Kovacs, Jenny Beygo & Elena Fragapane. (2012) Assessment of Antigen-Specific and Cross-Reactive Antibody Responses to an MF59-Adjuvanted A/H5N1 Prepandemic Influenza Vaccine in Adult and Elderly Subjects. Clinical and Vaccine Immunology 19:12, pages 1943-1948.
Crossref
Crossref
Young June Choe, Geun-Ryang Bae & Duk-hyoung Lee. (2012) No association between influenza A(H1N1)pdm09 vaccination and narcolepsy in South Korea: An ecological study. Vaccine 30:52, pages 7439-7442.
Crossref
Crossref
Stan L. Block, Guillermo M. Ruiz-Palacios, M. Lourdes Guerrero, Jenny Beygo, Victor Sales & Sandra J. Holmes. (2012) Dose-range Study of MF59-adjuvanted Versus Nonadjuvanted Monovalent A/H1N1 Pandemic Influenza Vaccine in Six- to Less Than Thirty-Six-month-old Children. Pediatric Infectious Disease Journal 31:7, pages e92-e98.
Crossref
Crossref
Christoph Hatz, Jakob P. Cramer, André Vertruyen, Tino F. Schwarz, Frank von Sonnenburg, Astrid Borkowski, Maria Lattanzi, Anne Katrin Hilbert, Giovanni Della Cioppa & Geert Leroux-Roels. (2012) A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations. Vaccine 30:32, pages 4820-4827.
Crossref
Crossref
Cynthia Nassim, Shane Christensen, Dan Henry, Sandra Holmes, Matthew Hohenboken & Niranjan Kanesa-Thasan. (2012) Identification of Antigen and Adjuvant Doses Resulting in Optimal Immunogenicity and Antibody Persistence up to 1 Year After Immunization With a Pandemic A/H1N1 Influenza Vaccine in Children 3 to <9 Years of Age. Pediatric Infectious Disease Journal 31:4, pages e59-e65.
Crossref
Crossref
Markku Partinen, Outi Saarenpää-Heikkilä, Ismo Ilveskoski, Christer Hublin, Miika Linna, Päivi Olsén, Pekka Nokelainen, Reija Alén, Tiina Wallden, Merimaaria Espo, Harri Rusanen, Jan Olme, Heli Sätilä, Harri Arikka, Pekka Kaipainen, Ilkka Julkunen & Turkka Kirjavainen. (2012) Increased Incidence and Clinical Picture of Childhood Narcolepsy following the 2009 H1N1 Pandemic Vaccination Campaign in Finland. PLoS ONE 7:3, pages e33723.
Crossref
Crossref
A. Rodríguez, L. Álvarez-Rocha, J.M. Sirvent, R. Zaragoza, M. Nieto, A. Arenzana, P. Luque, L. Socías, M. Martín, D. Navarro, J. Camarena, L. Lorente, S. Trefler, L. Vidaur, J. Solé-Violán, F. Barcenilla, A. Pobo, J. Vallés, C. Ferri, I. Martín-Loeches, E. Díaz, D. López, M.J. López-Pueyo, F. Gordo, F. del Nogal, A. Marqués, S. Tormo, M.P. Fuset, F. Pérez, J. Bonastre, B. Suberviola, E. Navas & C. León. (2012) Recommendations of the Infectious Diseases Work Group (GTEI) of the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC) and the Infections in Critically Ill Patients Study Group (GEIPC) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) for the diagnosis and treatment of influenza A/H1N1 in seriously ill adults admitted to the Intensive Care Unit. Medicina Intensiva (English Edition) 36:2, pages 103-137.
Crossref
Crossref
A. Rodríguez, L. Álvarez-Rocha, J.M. Sirvent, R. Zaragoza, M. Nieto, A. Arenzana, P. Luque, L. Socías, M. Martín, D. Navarro, J. Camarena, L. Lorente, S. Trefler, L. Vidaur, J. Solé-Violán, F. Barcenilla, A. Pobo, J. Vallés, C. Ferri, I. Martín-Loeches, E. Díaz, D. López, M.J. López-Pueyo, F. Gordo, F. del Nogal, A. Marqués, S. Tormo, M.P. Fuset, F. Pérez, J. Bonastre, B. Suberviola, E. Navas & C. León. (2012) Recomendaciones del Grupo de Trabajo Enfermedades Infecciosas (GTEI) de la Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias (SEMICYUC) y el Grupo de Estudio de Infecciones en el Paciente Crítico (GEIPC) de la Sociedad Española de Enfermedades Infecciosas y Microbiología clínica (SEIMC) para el diagnóstico y tratamiento de la gripe A/H1N1 en pacientes adultos graves hospitalizados en las Unidades de Cuidados Intensivos. Medicina Intensiva 36:2, pages 103-137.
Crossref
Crossref
Emmanuel Grimprel. (2012) Nouveautés vaccinales en médecine humaine. Bulletin de l'Académie Nationale de Médecine 196:3, pages 575-588.
Crossref
Crossref
Timo Vesikari, Aino Forstén, Karl-Heinz Herbinger, Giovanni Della Cioppa, Jenny Beygo, Astrid Borkowski, Nicola Groth, Mariaviviana Bennati & Frank von Sonnenburg. (2012) Safety and immunogenicity of an MF59®-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly. Vaccine 30:7, pages 1388-1396.
Crossref
Crossref
Birgitte Rahbek Kornum, Juliette Faraco & Emmanuel Mignot. (2011) Narcolepsy with hypocretin/orexin deficiency, infections and autoimmunity of the brain. Current Opinion in Neurobiology 21:6, pages 897-903.
Crossref
Crossref
Andrew J Broadbent & Kanta Subbarao. (2011) Influenza virus vaccines: lessons from the 2009 H1N1 pandemic. Current Opinion in Virology 1:4, pages 254-262.
Crossref
Crossref
S. Sohail AhmedStanley A. PlotkinSteven BlackRobert L. Coffman. (2011) Assessing the Safety of Adjuvanted Vaccines. Science Translational Medicine 3:93.
Crossref
Crossref